Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $13.22 Consensus PT from Analysts

Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus recommendation of “Buy” from the five analysts that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $13.22.

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Niagen Bioscience from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 22nd. Canaccord Genuity Group upped their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. Finally, Roth Capital reiterated a “buy” rating and issued a $23.00 price objective (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. State of Wyoming acquired a new position in Niagen Bioscience during the fourth quarter valued at approximately $39,000. Mercer Global Advisors Inc. ADV acquired a new position in Niagen Bioscience during the fourth quarter valued at approximately $53,000. Schonfeld Strategic Advisors LLC acquired a new position in Niagen Bioscience during the fourth quarter valued at approximately $67,000. Virtu Financial LLC acquired a new position in Niagen Bioscience during the fourth quarter valued at approximately $68,000. Finally, ProShare Advisors LLC acquired a new position in Niagen Bioscience during the fourth quarter valued at approximately $74,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Trading Up 3.8%

NASDAQ NAGE opened at $11.50 on Monday. The stock has a 50-day simple moving average of $11.98 and a 200 day simple moving average of $8.04. The company has a market capitalization of $905.86 million, a PE ratio of 67.65 and a beta of 2.14. Niagen Bioscience has a 12 month low of $2.53 and a 12 month high of $14.69.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.